Most recent reports demonstrated that the expression of HER2 was a predictor of poor prognosis for ovarian cancer [12, 16, 20, 26, 34–35, 37–38, 41], while others showed that the HER2 expression had no influence on the survival in ovarian cancer patients [6, 11, 13–15, 17–19, 21–25, 27–33, 36, 39–40]. This evidence concerns the gene ERBB2 and ovarian cancer.